Search results
Results From The WOW.Com Content Network
The Online News Act (French: Loi sur les nouvelles en ligne), known commonly as Bill C-18, is a Canadian federal statute.Introduced in the 44th Canadian Parliament, passed by the Senate on June 15, 2023, and receiving royal assent on June 22, 2023, the act will implement a framework under which digital news intermediaries (including search engines and social networking services) that hold an ...
In May 2008, the Canadian government led by Stephen Harper passed Bill C-22 (introduced in February 2007 and revised in August 2007) [3] to raise the age of consent from 14 to 16, while creating a close-in-age exemption for sex between 14–15 year olds and partners less than 5 years older, and keeping an existing close-in-age clause for sex ...
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Commonly known as Bill C-10, the bill was passed in the House of Commons on June 22, 2021, but failed to pass the Senate before Parliament was dissolved for a federal election. It was reintroduced with amendments as the Online Streaming Act during the first session of the 44th Canadian Parliament in February 2022, passed in the House of Commons ...
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
WASHINGTON (Reuters) -The U.S. Senate on Thursday was expected to advance a bill to require the federal government to detain migrants living in the U.S. illegally who are suspected of criminal ...
Supporters of the assisted dying Bill wept and hugged each other outside Parliament as the news came through that it had been passed by MPs. The crowd in Parliament Square erupted into cheers as ...
Patented Medicine Prices Review Board office in Ottawa. Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.